Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Decline in HPV-Related Cervical Cancer May Inform Screening and Vaccination Guidance for Other Tumor Types

May 20, 2021
By Audrey Sternberg
News
Article
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Seventeen years of data indicate that HPV-related cervical cancer incidence is declining, but other tumors related to the virus persist.

Evidence from a population-based study on the incidence of human papillomavirus (HPV)–related cancers indicate a marked decline in cervical carcinoma, potentially due to clear guidance regarding screening measures and HPV vaccination for vulnerable patient groups.1,2

On the other hand, the incidence of other HPV-related cancers without clear screening guidelines are on the rise in both men and women.

“In young women, cervical carcinoma is decreasing consistently with screening, and possibly vaccination, at the population level,” lead author Cheng-I Liao, MD, of Kaohsiung Veterans General Hospital in Kaohsiung, Taiwan, said during a presentation of the data during a media briefing leading up to the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

HPV is associated with more than 90% of cervical and anal cancers and 60% to 75% of oropharyngeal, vulvar, vaginal, and penile tumors.3 The purpose of the study was to assess trends in the incidence of HPV-associated cancer using the United States Cancer Statistics Database from 2001 to 2017.

In the 17-year timeframe, there were 657,317 cases of cancer, 393,298 (60%) of which were in women. The most commonly occurring cancer in female patients was cervical carcinoma (52%). In men (n = 264,019), the most common malignancy was oropharyngeal squamous cell carcinoma (SCC; 80%), which represents a 5-fold higher incidence compared with women.

Over the study period, cervical cancer incidence decreased by 1.03% per year (P <.05), but this rate was significantly higher in patients aged 20 to 24 years who saw a much greater decrease in disease incidence, at 4.63% per years. Similar effects were seen in women over the age of 65, who saw a greater than 2% incidence decline over the study period (P <.05). The investigators said this is likely due to the effects of HPV vaccination and screening.

However, other HPV-related cancers without standardized screening guidelines saw increases over the study period, with a 2.71% incidence rise per year in men and a 0.77% increase in women. Other HPV-associated cancers included anal and rectal SCC, oropharyngeal SCC, penile cancer, vulvar SCC, and vaginal SCC.

In women over the age of 50, the annual percentage change in the incidence of anal and rectal SCC was 3.55% (P <.001). When compared with the 1.53% decline in the incidence of cervical cancer in the same patient population (P <.001), trends suggest that HPV-related anal and rectal SCC will surpass its incidence in the coming decade, and likely in the next 5 years.

“The decrease in cervical cancer is welcome news and may reflect intensive efforts to screen and vaccinate patients at risk,” ASCO President Lori J. Pierce, MD, FASTRO, FASCO, said in a press release. “Clearly, this study shows that we still have a great deal of work to do in order to reverse the increasing incidence rates of other HPV-related cancers.”

The investigators plan to gather information from other databases about the rate of HPV testing and vaccination. Additional research will be necessary to tackle a lack of disease screening and vaccination recommendations for HPV-associated cancers other than cervical.

References

1. HPV associated cancers in the US over the last 17 years – has screening or vaccination made any difference? Presented at: 2021 ASCO Annual Meeting Virtual Embargoed Presscast; May 19, 2021; Virtual.

2. With Strong Screening and Vaccination Guidelines, Cervical Cancer Rates Drop; Other HPV-Related Cancers Are on the Rise. News release. American Society of Clinical Oncology. May 19, 2021. Accessed May 19, 2021. https://bit.ly/3ylfjJ1

3. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086. doi:10.1093/jnci/djv086

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content
Advertisement

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.

YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors

Roman Fabbricatore
July 7th 2025
Article

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.


Male Cancer Survivors in Physically Demanding Jobs Need More Support

Male Cancer Survivors in Physically Demanding Jobs Need More Support

Ariana Pelosci
July 5th 2025
Article

Findings from a WeCanWork study showed that men who work laborious jobs need additional support during and after cancer treatment.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.


Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Related Content
Advertisement

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.

YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors

Roman Fabbricatore
July 7th 2025
Article

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.


Male Cancer Survivors in Physically Demanding Jobs Need More Support

Male Cancer Survivors in Physically Demanding Jobs Need More Support

Ariana Pelosci
July 5th 2025
Article

Findings from a WeCanWork study showed that men who work laborious jobs need additional support during and after cancer treatment.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.


Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.